Paloma Troyano-Hernáez

Mrs. Paloma Troyano-Hernáez

IRYCIS-Hospital Ramón y Cajal
+2
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
Roberto ReinosaRoberto Reinosa
Roberto Reinosa
Africa HolguínAfrica Holguín
Africa Holguín
Monitoring acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity and emerging mutations in this ongoing pandemic is crucial for understanding its evolution and assuring the performance of diagnostic tests, vaccines, and therapies against coronavirus disease (COVID-19). This study reports on the amino acid (aa) conservation degree and the global and regional temporal evolution by epidemiological week for each residue of the following four structural SARS-CoV-2 proteins: spike, envelope, membrane, and nucleocapsid. All, 105,276 worldwide SARS-CoV-2 complete and partial sequences from 117 countries available in the Global Initiative on Sharing All Influenza Data (GISAID) from 29 December 2019 to 12 September 2020 were downloaded and processed using an in-house bioinformatics tool. Despite the extremely high conservation of SARS-CoV-2 structural proteins (>99%), all presented aa changes, i.e., 142 aa changes in 65 of the 75 envelope aa, 291 aa changes in 165 of the 222 membrane aa, 890 aa changes in 359 of the 419 nucleocapsid aa, and 2671 changes in 1132 of the 1273 spike aa. Mutations evolution differed across geographic regions and epidemiological weeks (epiweeks). The most prevalent aa changes were D614G (81.5%) in the spike protein, followed by the R203K and G204R combination (37%) in the nucleocapsid protein. The presented data provide insight into the genetic variability of SARS-CoV-2 structural proteins during the pandemic and highlights local and worldwide emerging aa changes of interest for further SARS-CoV-2 structural and functional analysis.

22 August 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
PDF file
FLFernando Lázaro-Perona
Fernando Lázaro-Perona
ASAlma Sotillo
Alma Sotillo
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
RGRosa Gómez-Gil
Rosa Gómez-Gil
ÁVÁngela de la Vega-Bueno
Ángela de la Vega-Bueno
JMJesús Mingorance
Jesús Mingorance

Verified
Journal Article
Open access
PDF file
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
Roberto ReinosaRoberto Reinosa
Roberto Reinosa
Africa HolguínAfrica Holguín
Africa Holguín
Monitoring SARS-CoV-2’s genetic diversity and emerging mutations in this ongoing pandemic is crucial to understanding its evolution and ensuring the performance of COVID-19 diagnostic tests, vaccines, and therapies. Spain has been one of the main epicenters of COVID-19, reaching the highest number of cases and deaths per 100,000 population in Europe at the beginning of the pandemic. This study aims to investigate the epidemiology of SARS-CoV-2 in Spain and its 18 Autonomous Communities across the six epidemic waves established from February 2020 to January 2022. We report on the circulating SARS-CoV-2 variants in each epidemic wave and Spanish region and analyze the mutation frequency, amino acid (aa) conservation, and most frequent aa changes across each structural/non-structural/accessory viral protein among the Spanish sequences deposited in the GISAID database during the study period. The overall SARS-CoV-2 mutation frequency was 1.24 × 10−5. The aa conservation was >99% in the three types of protein, being non-structural the most conserved. Accessory proteins had more variable positions, while structural proteins presented more aa changes per sequence. Six main lineages spread successfully in Spain from 2020 to 2022. The presented data provide an insight into the SARS-CoV-2 circulation and genetic variability in Spain during the first two years of the pandemic.

11 October 2021 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
Roberto ReinosaRoberto Reinosa
Roberto Reinosa
MBMaría Concepción Burgos
María Concepción Burgos
Africa HolguínAfrica Holguín
Africa Holguín
HIV variants carry natural polymorphisms related to drug resistance (R-markers) fixed during viral evolution in the absence of antiretroviral therapy (ART) that may impact on drug susceptibility and resistance pathways. We aimed to identify the HIV type 2 (HIV-2) variant-specific R-markers at Pol in all available sequences from ART-naive subjects deposited in Los Alamos database according to reported HIV-2 drug resistance-associated mutations (DRMs) and report the performance of two online HIV-2 resistance interpretation tools (HIV2EU Tool and Stanford HIVdb Program for HIV-2) to detect them. From a total of 587 sequences, we found 23 R-markers in low frequency, in groups A, B, and G. Four were present in >10% of the sequences with no direct impact on antiretroviral susceptibility. HIV2EU Tool detected one, whereas Stanford program all four. Stanford new tool, although still under development, seems effective in detecting HIV-2 DRMs and may prove a useful tool for HIV-2 resistance interpretation when fully developed.

17 October 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
PHPedro Herrador
Pedro Herrador
FGFrancisco Gea
Francisco Gea
BRBeatriz Romero-Hernández
Beatriz Romero-Hernández
GRGabriel Reina
Gabriel Reina
Africa HolguínAfrica Holguín
Africa Holguín
The scale-up of hepatitis C virus (HCV) diagnosis and treatment requires affordable and simple tools to improve access to care, especially in low- and middle-income settings with limited infrastructure or high-risk populations. Dried blood and plasma samples (DBS and DPS) are useful alternative for hepatitis C detection in settings lacking adequate infrastructure. We evaluated the performance of DBS and DPS vs plasma in a point-of-care HCV RNA quantitative assay (Xpert HCV Viral Load-Cepheid), and compared HCV core antigen (HCVcAg) detection by the Architect HCV core antigen assay (Abbott) in DBS vs serum. The dried samples were stored at room temperature for different storage times to reproduce the time from sampling to testing in settings with centralized diagnosis or when testing mobile populations. HCV RNA quantification in DBS and DPS presented 100% sensitivity and specificity and a high correlation for up to 3 months of storage. HCV viremia showed a mean decrease of 0.5 log 10 IU/mL (DBS) and 0.3 log 10 IU/mL (DPS) for storage times up to 1 month. Architect HCVcAg detection presented high sensitivity/specificity (96%/100%) in DBS tested immediately after sampling, decreasing to 86% sensitivity after 7 days of storage. However, sensitivity increased when an optimized cut-off was applied for each storage time. We conclude that DBS and DPS are suitable samples for HCV RNA detection and quantification, being DPS more reliable for shorter storage times. DBS can be also used for HCVcAg qualitative detection and the sensitivity can be increased when adjusting the cut-off values. IMPORTANCE: Hepatitis C infection remains a global burden despite the effectiveness of antivirals. In the WHO roadmap to accomplish HCV elimination by 2030, HCV diagnosis is one of the main targets. However, identifying patients in resource-limited settings and high-risk populations with limited access to healthcare remains a challenge and requires innovative approaches that allow decentralized testing. The significance of our research is in verifying the good performance of dried samples for HCV diagnosis using two different diagnostics assays and considering the effect of room temperature storage in this sample format. We confirmed dried samples are an interesting alternative for HCV screening and reflex testing in resource-limited settings or high-risk populations.

1 December 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Paloma Troyano-HernáezPaloma Troyano-Hernáez
Paloma Troyano-Hernáez
AGAlmudena Gutiérrez-Arroyo
Almudena Gutiérrez-Arroyo
RGRosa Gómez-Gil
Rosa Gómez-Gil
JMJesús Mingorance
Jesús Mingorance
FLFernando Lázaro-Perona
Fernando Lázaro-Perona
Carbapenemase-producing Enterobacteriaceae (CPE) have become a major public health concern worldwide (1).…